scispace - formally typeset
L

Landon S. King

Researcher at Johns Hopkins University

Publications -  77
Citations -  8728

Landon S. King is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Lung injury & Aquaporin. The author has an hindex of 40, co-authored 76 publications receiving 8018 citations. Previous affiliations of Landon S. King include Johns Hopkins University School of Medicine.

Papers
More filters
Journal ArticleDOI

Aquaporin water channels – from atomic structure to clinical medicine

TL;DR: The water permeability of biological membranes has been a longstanding problem in physiology, but the proteins responsible for this remained unknown until discovery of the aquaporin 1 (AQP1) water channel protein.
Journal ArticleDOI

From structure to disease: the evolving tale of aquaporin biology

TL;DR: This work states that the discovery of aquaporins has stimulated a reconsideration of membrane water permeability by investigators across a wide range of disciplines and indicates diverse roles in the regulation of water homeostasis.
Journal ArticleDOI

Pathophysiology of the aquaporin water channels

TL;DR: Specific regulation of membrane water permeability will likely prove important to understanding edema formation and fluid balance in both normal physiology and disease.
Journal ArticleDOI

Diverse macrophage populations mediate acute lung inflammation and resolution

TL;DR: Experimental animal models of acute lung injury (ALI) reproduce key components of the injury and resolution phases of human ARDS and provide a methodology to explore mechanisms and potential new therapies and highlight human studies that relate to the diverse role of macrophages in initiation and resolution of ALI and ARDS.
Journal ArticleDOI

CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury

TL;DR: Results indicate that Tregs modify innate immune responses during resolution of lung injury and suggest potential targets for treating ALI, for which there are no specific therapies currently available.